Cure8 research brief
Patients, clinicians, and payers may care because the analysis addresses the relative economic value of two approved biologic options (vedolizumab and risankizumab) for Crohn’s disease treatment in Italy and could influence treatment choice and reimbursement discussions.
Clinicians treating Crohn’s disease, health-system budget holders and payers in Italy, patients and caregivers considering biologic therapy, and health economics researchers.
The study used a cost-per-responder model with efficacy inputs taken from a published matching-adjusted indirect comparison and included Italian drug acquisition and administration costs. In the primary analysis VDZ showed a lower cost per remission (€114,098) than RZB (€285,939) at 1 year.
Sensitivity analyses varying remission rates by ±25% and applying substantial price discounts still found VDZ had a lower cost per remission. The paper reports economic modeling results specific to the Italian healthcare setting and to the inputs and methods described; it does not present new randomized head-to-head clinical trial data.
The graphical abstract and full methods are provided in the article for readers who want more detail. Key takeaway: for health-system or policy discussions in Italy, the model in this paper suggests VDZ may be a more resource-efficient choice than RZB to achieve 1-year clinical remission, within the limits of the model’s assumptions and input data.
This is a model-based cost-per-responder analysis using efficacy inputs from an indirect comparison rather than from a direct head-to-head trial; results depend on those efficacy estimates, cost inputs, and modeling choices. Findings apply to the Italian cost context and the 1-year time horizon used by the authors.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
